Dalton Pharma Proceeds with Other Activities to Manufacture Nanoparticle Formulations

Image Credits: PitchBook

Announcement

The onco-innovations limited is proud to confirm that Dalton Pharma Services has proceeded with activities for manufacturing onco’s exclusive nanoparticle formulation, also known as PEO-b-PBz-CL, a major component of the onco’s novel drug delivery platform, which is engineered for use in conjunction with the company’s exclusive polynucleotide kinase phosphatase (PNKP) inhibitor. The manufacturing efforts are planned to create the nanoparticle material that is needed to advance preclinical studies. The production campaign will consist of scale-up activities and the process of optimization to develop reproducible methods for the synthesis of PEO-b-PBz-CL, while promising that the formulation will effectively meet the molecular weight, residual solvent levels, and quality specifications for purity.

Onco-innovation is a dedicated Canadian-based company in cancer research and treatment, specializing in oncology. The company’s mission is to serve the treatment and prevention of cancer by focusing on research and creative solutions. The company is an exclusive license holder securing the patented technology required for the solid tumours. With Dalton’s continuation of the activity to supply preclinical animal studies, the Onco will take a step ahead with the new formulation in the global healthcare market, with the new clinical solution to further contribute largely to the preclinical animal studies. The manufacturing of the nanoparticle formulation might help numerous other clinical studies to discover and promote excellent health potential in the vast advanced healthcare spectrum.

Dalton’s Initiatives

Dalton has long elaborated the feasibility at the 10-gram scale and will now concentrate on diminishing residual catalyst content and leveling up production to 100 grams, following the elaborative batch at the 350-gram scale. These activities are engineered to enable enough quantity of nanoparticle material for the development of the formulation. Alongside creating the analytical data required to help with the regulatory filings, and the obvious transformation to good manufacturing practice (GMP) manufacturing.

By involving Dalton, Onco has gained an advantage from the regulatory experience and technical expertise of one of Canada’s well-known manufacturing organizations and contract development. Dalton’s work will deliver a robust development package consisting full analytical process and characterization documentation, to commit to an easy pathway towards clinical readiness of the nanoparticle-based platform.

CEO of onco-innovations, Thomas O’Shaughnessy, said, “Advancing the nanoparticle formulation demonstration will help us by updating our next phase of development, enhancing our way towards the clinical opportunities we are ambitious enough to reach.”